Collectively, targeting TRPV4 can simultaneously act on tumor cells and their “hijacked” immune cells, reduce the production of inflammatory factors, and finally ameliorate the inflammatory microenvironment for tumor metastasis. This evidence concerns the gene TRPV4 and neoplasm.